SLU-PP-332 dosing (preclinical regimens)
Human schedule
Controlled data on this compound are limited. The regimens below were gathered from public sources online (studies and protocols) and are given as a reference, not a usage plan.
SLU-PP-332 has been administered subcutaneously in reported use (reconstituted 5 mg vial); the figures below are generalized from descriptive community protocols, as no human clinical trials exist (all published data are in mice).
This is a concise reference to regimens described for adults; it is not an individual prescription.
| Period / condition | Dose | Escalation |
|---|---|---|
| Start | 250 mcg subcutaneously, once daily | Starting dose |
| Intermediate | 500 mcg – 1 mg subcutaneously, once daily | Increase if needed |
| Upper level | 1.5 mg subcutaneously, once daily | Maximum in this schedule |